Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | NMT2 | O60551 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26281010 | 0.91 | CPB1 (0.47) | CPB1CPB2SIRT2SIRT1MMP3 | |
| SCHEMBL26279273 | 0.88 | SIRT2 (0.44) | CPB1CPB2SIRT2SIRT1MMP3 | |
| SCHEMBL25100592 | 0.84 | SIRT2 (0.42) | CPB1CPB2SIRT2SIRT1MMP3 | |
| SCHEMBL25052999 | 0.83 | SIRT2 (0.51) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL26192867 | 0.80 | MMP3 (0.43) | CPB1CPB2SIRT2SIRT1MMP3 | |
| SCHEMBL26017207 | 0.80 | MMP3 (0.43) | CPB1CPB2SIRT2SIRT1MMP3 | |
| SCHEMBL23425577 | 0.78 | KLKB1 (0.45) | SIRT2SIRT1KLKB1ROCK2 | |
| SCHEMBL22452312 | 0.77 | SIRT2 (0.44) | CPB1CPB2SIRT2SIRT1MMP3 | |
| SCHEMBL17683439 | 0.77 | SIRT2 (0.45) | SIRT2SIRT1SIRT3SIRT5ROCK2 | |
| SCHEMBL26033430 | 0.76 | SIRT1 (0.45) | SIRT2SIRT1MMP3SIRT3KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293710-A1 | ANTIBODY-DRUG CONJUGATES AGAINST THE RECEPTOR TYROSINE KINASE EPHA5 | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293710-A1 | ANTIBODY-DRUG CONJUGATES AGAINST THE RECEPTOR TYROSINE KINASE EPHA5 | EPHA5, EPHA3, EPHA1 | CPB1 1627/4885CPB2 1832/4885SIRT2 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.